1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
El Mundo on MSN1d
Ozempic and Viagra, among the more than 80 drugs expected to work against Alzheimer's in the coming yearsIn recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...
"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...
Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...
The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Maturing Plaques. The oldest plaques (left) contain β-sheets (red) and dense fibrillar cores (blue), while younger plaques (middle) lack dense cores, and the youngest (right) lack either. [Courtesy of ...
AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...
Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
New research offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis. Alzheimer’s disease is a leading cause of death among those aged 65 or older. As the most common ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback